News about Bioatla Inc

Unraveling the KRAS Conundrum Promising Insights from BioAtlas Mecbotamab Vedotin in Advanced NSCLC Treatment
Dec 29 2024
In the realm of oncology, few challenges have been as vexing as the treatment of non-small cell lung cancer (NSCLC), particularly in patients harbouri...

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Ma...
Sep 16 2024
BioAtla Demonstrates Promising Phase 2 Clinical Trial Results for Ozuriftamab Vedotin in Treating Heavily Pretreated Squamous Cell Carcinoma of the H...

BioAtla Inc (BCAB) Trailing the Markets Performance
Jul 19 2024
In recent developments, BioAtla Inc s shares have been trailing the performance of the entire market. This analysis will explore key events surroundin...

BioAtla Announces Participation in Jefferies Global Healthcare Conference to Showcase B...
May 29 2024
BioAtla, a leading clinical-stage biotechnology company, has recently announced its participation in the upcoming Jefferies Global Healthcare Conferen...

BioAtla to Present Groundbreaking Research on Conditionally Active Biologic Antibody Therapeutics at ASCO 2024 Annual Meeting
Apr 24 2024
BioAtla, Inc., a prominent global clinical-stage biotechnology company, has recently made an exciting announcement regarding its participation in the ...

BioAtla Hosts Virtual R&D Day to Unveil Promising Phase 1 Data for BA3071 CAB-CTLA-4 in Multiple Solid Tumor Types
Dec 06 2023
BioAtla, a distinguished global clinical-stage biotechnology company specializing in the development of Conditionally Active Biologic (CAB) ...

BioAtla*s BA3011: Unveiling a Ray of Hope for Heavily Pre-Treated NSCLC Patients
Dec 05 2023
In a recent press release, BioAtla, a leading clinical-stage biopharmaceutical company, presented data from their Phase 2 clinical trial at ...

Bioatla Inc*s Financial Quarter Plunges: Operating Shortfall and Zero Revenue Spark Investor Worries
Nov 08 2023
The third quarter of 2023 has proven to be a challenging period for Bioatla Inc, a global clinical-stage biotechnology company focused on the developm...